CorMedix reports its next earnings event on August 13, and the setup is defined by one uncomfortable tension: short sellers have built a substantial position in a stock down 16% over the past month, yet options traders remain notably relaxed heading into the print.
Short interest at nearly 20% of free float is the dominant feature of this story. At 19.5% of free float — up 7.4% over the past 30 days — short positioning is high by any measure for a small-cap pharmaceutical name. The borrow market adds texture: availability has tightened sharply this week, dropping to roughly 21%, meaning only about one share remains available for every four already lent out. That compares with a floor of just 0.26% recorded over the past 52 weeks, and as recently as July 13 availability reached that near-zero reading before releasing pressure. Cost to borrow is modest at 1.0% — a 47% jump on the week but still well below levels that would indicate a genuine squeeze — which suggests short sellers face no meaningful friction holding their positions into the event. The ORTEX short score has held in a tight range near 82.5 for the past two weeks, ranking in the 2nd percentile of its peer universe on short score and 3rd percentile on days-to-cover. Positioning here looks entrenched rather than opportunistic.
Options traders are telling a different story, and the contrast is worth naming. The put/call ratio is running at 0.49, barely above its 20-day average of 0.47 and less than one standard deviation above the mean. For a stock carrying nearly 20% short interest and heading into an earnings event five days away, that is a strikingly low demand for downside protection. The PCR has ranged between 0.28 and 0.83 over the past year; the current reading puts it firmly in the middle of that range. Options traders are not hedging into this earnings the way the short book would imply they should be.
The Street broadly agrees that the stock is undervalued, though the conviction gap between analyst targets and the current price is significant. The mean price target across covering analysts is $15.00 against a close of $7.44 — roughly double. Ratings are uniformly positive, with active Outperform and Buy ratings from RBC Capital, Leerink Partners, Needham, and HC Wainwright. RBC did trim its target from $14 to $13 in early July, the only recent move, though it kept its Outperform rating intact. The bull case rests on DefenCath's phase 3 ReSPECT trial results demonstrating efficacy in preventing catheter-related bloodstream infections in hemodialysis patients, with analysts pointing to potential peak sales approaching $190 million in the current indication alone. The bear case is straightforward: CorMedix is a single-product company whose commercial execution, label expansion pathway, and competitive positioning all remain unproven at scale. Valuation multiples reflect the tension — the PE has contracted by about 1.1 turns over the past 30 days, while EV/EBITDA has edged slightly higher.
Institutional ownership adds a wrinkle. Vanguard Capital Management reported building a new position of 3.6 million shares as of June 30 — a meaningful entry for a stock with roughly 78 million shares outstanding. Royce & Associates similarly added 1.6 million shares in early July, bringing its total to 1.9 million. Those two new or expanded positions land alongside a top holder with a 5.9% stake, bringing identifiable institutional interest to a non-trivial share of the float. On the other side, the insider data is stale — the most recent reported trades were from January 2026 — and cannot be relied upon as a current signal.
Earnings history provides limited but directionally useful context. The June 23 print produced a 4.9% drop on the day and a further 11% decline over the following five days. The May 14 report went the other way, with a 0.7% gain on the day extending to a 7.5% gain over five sessions. The sample is small and the outcomes diverged, which makes the direction of the August 13 print hard to read from history alone. What is clear is that the next catalyst to watch is whether DefenCath's commercial uptake numbers — and any update on the label expansion program — either validate or challenge the large gap between where the stock trades and where the analysts have their targets.
See the live data behind this article on ORTEX.
Open CRMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
